{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:24:58Z","timestamp":1792167898983,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T00:00:00Z","timestamp":1428710400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1007\/s00280-015-2738-3","type":"journal-article","created":{"date-parts":[[2015,4,9]],"date-time":"2015-04-09T23:42:04Z","timestamp":1428622924000},"page":"1183-1189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial"],"prefix":"10.1007","volume":"75","author":[{"given":"D.","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Tsubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ariyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Miyaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sueoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Teramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Odagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Nagumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,11]]},"reference":[{"issue":"5","key":"2738_CR1","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.1349-7006.2010.01519.x","volume":"101","author":"HR Shin","year":"2010","unstructured":"Shin HR, Boniol M, Joubert C, Hery C, Haukka J, Autier P, Nishino Y, Sobue T, Chen CJ, You SL, Ahn SH, Jung KW, Law SC, Mang O, Chia KS (2010) Secular trends in breast cancer mortality in five East Asian populations: Hong Kong, Japan, Korea, Singapore and Taiwan. Cancer Sci 101(5):1241\u20131246. doi: 10.1111\/j.1349-7006.2010.01519.x","journal-title":"Cancer Sci"},{"key":"2738_CR2","doi-asserted-by":"crossref","first-page":"9081","DOI":"10.1186\/1757-1626-2-9081","volume":"2","author":"T Kawaguchi","year":"2009","unstructured":"Kawaguchi T, Iwase S, Takeuchi H, Ikeda A, Kuroda Y, Sakata N, Umeda M, Kobara K, Matsunaga T, Unezaki S, Nagumo Y (2009) Chemotherapy with low-dose capecitabine as palliative treatment in a patient with metastatic breast cancer: a case report. Cases J 2:9081. doi: 10.1186\/1757-1626-2-9081","journal-title":"Cases J"},{"issue":"12","key":"2738_CR3","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","volume":"26","author":"T Burzykowski","year":"2008","unstructured":"Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, L\u00fcck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26(12):1987\u20131992","journal-title":"J Clin Oncol"},{"issue":"9","key":"2738_CR4","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1023\/A:1012281104865","volume":"12","author":"JA Oshaughnessy","year":"2001","unstructured":"Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, Mauriac L, Osterwalder B, Burger HU, Laws S (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced\/metastatic breast cancer. Ann Oncol 12(9):1247\u20131254","journal-title":"Ann Oncol"},{"issue":"8","key":"2738_CR5","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","volume":"34","author":"M Miwa","year":"1998","unstructured":"Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H (1998) Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 34(8):1274\u20131281","journal-title":"Eur J Cancer"},{"issue":"7","key":"2738_CR6","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/1097-0142(20011001)92:7<1759::AID-CNCR1691>3.0.CO;2-A","volume":"92","author":"JL Blum","year":"2001","unstructured":"Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B (2001) Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92(7):1759\u20131768","journal-title":"Cancer"},{"issue":"1","key":"2738_CR7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","volume":"27","author":"CM Walko","year":"2005","unstructured":"Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27(1):23\u201344. doi: 10.1016\/j.clinthera.2005.01.005","journal-title":"Clin Ther"},{"issue":"6","key":"2738_CR8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1159\/000322660","volume":"5","author":"D Yamamoto","year":"2010","unstructured":"Yamamoto D, Yamamoto C, Iwase S, Kuroda Y, Odagiri H, Nagumo Y (2010) Efficacy of vitamin E treatment for hand-foot syndrome in patients receiving capecitabine. Breast Care (Basel) 5(6):415\u2013416. doi: 10.1159\/000322660","journal-title":"Breast Care (Basel)"},{"issue":"8","key":"2738_CR9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/annonc\/mdg346","volume":"14","author":"P Reichardt","year":"2003","unstructured":"Reichardt P, Von Minckwitz G, Thuss-Patience PC, Jonat W, Kolbl H, Janicke F, Kieback DG, Kuhn W, Schindler AE, Mohrmann S, Kaufmann M, Luck HJ (2003) Multicenter phase II study of oral capecitabine (Xeloda(\u201c)) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14(8):1227\u20131233","journal-title":"Ann Oncol"},{"issue":"4","key":"2738_CR10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejca.2003.11.007","volume":"40","author":"P Fumoleau","year":"2004","unstructured":"Fumoleau P, Largillier R, Clippe C, Dieras V, Orfeuvre H, Lesimple T, Culine S, Audhuy B, Serin D, Cure H, Vuillemin E, Morere JF, Montestruc F, Mouri Z, Namer M (2004) Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40(4):536\u2013542. doi: 10.1016\/j.ejca.2003.11.007","journal-title":"Eur J Cancer"},{"issue":"4","key":"2738_CR11","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.2005.05.098","volume":"23","author":"KD Miller","year":"2005","unstructured":"Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS (2005) Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23(4):792\u2013799. doi: 10.1200\/JCO.2005.05.098","journal-title":"J Clin Oncol"},{"issue":"2","key":"2738_CR12","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/BF02968301","volume":"11","author":"T Saek","year":"2004","unstructured":"Saek T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, Morimoto K, Kimura M, Aoyama H, Ota J, Noguchi S, Taguchi T (2004) A phase II study of S-1 in patients with metastatic breast cancer\u2013a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer 11(2):194\u2013202","journal-title":"Breast Cancer"},{"issue":"3","key":"2738_CR13","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00280-007-0497-5","volume":"61","author":"D Yamamoto","year":"2008","unstructured":"Yamamoto D, Iwase S, Kitamura K, Odagiri H, Yamamoto C, Nagumo Y (2008) A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol 61(3):509\u2013514. doi: 10.1007\/s00280-007-0497-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2738_CR14","first-page":"3827","volume":"30","author":"D Yamamoto","year":"2010","unstructured":"Yamamoto D, Iwase S, Yoshida H, Kuroda Y, Yamamoto C, Kitamura K, Odagiri H, Nagumo Y (2010) Efficacy of S-1 in patients with capecitabine-resistant breast cancer-Japan Breast Cancer Research Network (JBCRN) 04-1 trial. Anticancer Res 30(9):3827\u20133831","journal-title":"Anticancer Res"},{"issue":"3","key":"2738_CR15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jjco\/hyn001","volume":"38","author":"T Shien","year":"2008","unstructured":"Shien T, Shimizu C, Akashi-Tanaka S, Yonemori K, Kohno T, Hojo T, Ando M, Katsumata N, Kinoshita T, Fujiwara Y (2008) Clinical efficacy of S-1 in pretreated metastatic breast cancer patients. Jpn J Clin Oncol 38(3):172\u2013175. doi: 10.1093\/jjco\/hyn001","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"2738_CR16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12282-008-0073-9","volume":"16","author":"Y Ito","year":"2009","unstructured":"Ito Y, Osaki Y, Tokudome N, Sugihara T, Takahashi S, Iwase T, Hatake K (2009) Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine. Breast Cancer 16(2):126\u2013131. doi: 10.1007\/s12282-008-0073-9","journal-title":"Breast Cancer"},{"issue":"6","key":"2738_CR17","first-page":"1531","volume":"25","author":"M Nukatsuka","year":"2004","unstructured":"Nukatsuka M, Fujioka A, Nakagawa F, Oshimo H, Kitazato K, Uchida J, Sugimoto Y, Nagayama S, Fukushima M (2004) Antimetastatic and anticancer activity of S-1, a new oral dihydropyrimidine-dehydrogenase-inhibiting fluoropyrimidine, alone and in combination with paclitaxel in an orthotopically implanted human breast cancer model. Int J Oncol 25(6):1531\u20131536","journal-title":"Int J Oncol"},{"issue":"8","key":"2738_CR18","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.3390\/molecules13081897","volume":"13","author":"GV Koukourakis","year":"2008","unstructured":"Koukourakis GV, Kouloulias V, Koukourakis MJ, Zacharias GA, Zabatis H, Kouvaris J (2008) Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment: a review. Molecules 13(8):1897\u20131922","journal-title":"Molecules"},{"issue":"4","key":"2738_CR19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/sj.bjc.6604536","volume":"99","author":"JL Lee","year":"2008","unstructured":"Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ (2008) A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer 99(4):584\u2013590. doi: 10.1038\/sj.bjc.6604536","journal-title":"Br J Cancer"},{"issue":"13","key":"2738_CR20","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1200\/JCO.2007.15.2090","volume":"26","author":"DG Haller","year":"2008","unstructured":"Haller DG, Cassidy J, Clarke SJ, Cunningham D, Van Cutsem E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ, Allegra C, Bertino JR, Douillard JY, Gustavsson BG, Milano G, O\u2019Connell M, Rustum Y, Tabernero J, Gilberg F, Sirzen F, Twelves C (2008) Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 26(13):2118\u20132123. doi: 10.1200\/JCO.2007.15.2090","journal-title":"J Clin Oncol"},{"issue":"6","key":"2738_CR21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1600-0560.1999.tb01846.x","volume":"26","author":"MM Asgari","year":"1999","unstructured":"Asgari MM, Haggerty JG, McNiff JM, Milstone LM, Schwartz PM (1999) Expression and localization of thymidine phosphorylase\/platelet-derived endothelial cell growth factor in skin and cutaneous tumors. J Cutan Pathol 26(6):287\u2013294","journal-title":"J Cutan Pathol"},{"issue":"18","key":"2738_CR22","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810\u20131820. doi: 10.1056\/NEJMoa072252","journal-title":"N Engl J Med"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2738-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-015-2738-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-015-2738-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T06:07:35Z","timestamp":1559023655000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-015-2738-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,11]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["2738"],"URL":"https:\/\/doi.org\/10.1007\/s00280-015-2738-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,11]]}}}